KR102103395B1 - 브루톤 티로신 키나제의 억제제로서의 폴리사이클릭 화합물 - Google Patents
브루톤 티로신 키나제의 억제제로서의 폴리사이클릭 화합물 Download PDFInfo
- Publication number
- KR102103395B1 KR102103395B1 KR1020187018900A KR20187018900A KR102103395B1 KR 102103395 B1 KR102103395 B1 KR 102103395B1 KR 1020187018900 A KR1020187018900 A KR 1020187018900A KR 20187018900 A KR20187018900 A KR 20187018900A KR 102103395 B1 KR102103395 B1 KR 102103395B1
- Authority
- KR
- South Korea
- Prior art keywords
- oxo
- thia
- carboxamide
- dihydro
- triazaacenaphthylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 ***N(c1c(c(N2)c(C(N3CCCC3)=O)[s]3)c3ncc1)C2=O Chemical compound ***N(c1c(c(N2)c(C(N3CCCC3)=O)[s]3)c3ncc1)C2=O 0.000 description 11
- YXWOWTHSPPWVAZ-QZTJIDSGSA-N C=CC(N[C@H](CCC1)C[C@@H]1NC(c([s]c1nccc(N2c(nc3)ccc3Oc3ccccc3)c11)c1NC2=O)=O)=O Chemical compound C=CC(N[C@H](CCC1)C[C@@H]1NC(c([s]c1nccc(N2c(nc3)ccc3Oc3ccccc3)c11)c1NC2=O)=O)=O YXWOWTHSPPWVAZ-QZTJIDSGSA-N 0.000 description 2
- YKJIFWFLUQFQPP-ZFNHKAKMSA-N C=CC(/N=C(\CCCC1)/[C@@H]1NC(c([s]c1nccc(N2c(cc3)ccc3Oc3ccccc3)c11)c1NC2=O)=O)=O Chemical compound C=CC(/N=C(\CCCC1)/[C@@H]1NC(c([s]c1nccc(N2c(cc3)ccc3Oc3ccccc3)c11)c1NC2=O)=O)=O YKJIFWFLUQFQPP-ZFNHKAKMSA-N 0.000 description 1
- AMKOMDRNDUXHIC-UHFFFAOYSA-N C=CC(NC(CCC1)C1NC(c([s]c1c2c(N3c4cccnc4)ccn1)c2NC3=O)=O)=O Chemical compound C=CC(NC(CCC1)C1NC(c([s]c1c2c(N3c4cccnc4)ccn1)c2NC3=O)=O)=O AMKOMDRNDUXHIC-UHFFFAOYSA-N 0.000 description 1
- MWFIXLOMZIFJCH-RBUKOAKNSA-N C=CC(N[C@@H](CCC1)[C@@H]1NC(c([s]c1nccc(N2c(nc3)ccc3Oc3ccccc3)c11)c1NC2=O)=O)=O Chemical compound C=CC(N[C@@H](CCC1)[C@@H]1NC(c([s]c1nccc(N2c(nc3)ccc3Oc3ccccc3)c11)c1NC2=O)=O)=O MWFIXLOMZIFJCH-RBUKOAKNSA-N 0.000 description 1
- XVLIKCUEMWVBPD-RBUKOAKNSA-N C=CC(N[C@@H](CCCC1)[C@@H]1NC(c([s]c1nccc(N2c(cn3)cnc3Oc3ccccc3)c11)c1NC2=O)=O)=O Chemical compound C=CC(N[C@@H](CCCC1)[C@@H]1NC(c([s]c1nccc(N2c(cn3)cnc3Oc3ccccc3)c11)c1NC2=O)=O)=O XVLIKCUEMWVBPD-RBUKOAKNSA-N 0.000 description 1
- BVJBZAJSQKJWBL-WOJBJXKFSA-N C=CC(N[C@H](CCCC1)[C@@H]1NC(c([s]c1nccc(N2c3ccnc(-c4ccccc4)c3)c11)c1NC2=O)=O)=O Chemical compound C=CC(N[C@H](CCCC1)[C@@H]1NC(c([s]c1nccc(N2c3ccnc(-c4ccccc4)c3)c11)c1NC2=O)=O)=O BVJBZAJSQKJWBL-WOJBJXKFSA-N 0.000 description 1
- IDZXZIJQWJUFQQ-QTFYQYEZSA-N CC(C)Cc(cc1C)ncc1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@H]3NC(/C=C/CNC(CCCC(NCCCOCCOCCOCCCNC(CCCC[C@@H]([C@H]3N4)SC[C@@H]3NC4=O)=O)=O)=O)=O)=O)[s]3)c3ncc1)C2=O Chemical compound CC(C)Cc(cc1C)ncc1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@H]3NC(/C=C/CNC(CCCC(NCCCOCCOCCOCCCNC(CCCC[C@@H]([C@H]3N4)SC[C@@H]3NC4=O)=O)=O)=O)=O)=O)[s]3)c3ncc1)C2=O IDZXZIJQWJUFQQ-QTFYQYEZSA-N 0.000 description 1
- PYJBXFHIRKFKPI-IXBQUWKISA-N CC(C)Cc(nc1)cc(C)c1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@H]3NC(/C(/C#N)=C/C3CC3)=O)=O)[s]3)c3ncc1)C2=O Chemical compound CC(C)Cc(nc1)cc(C)c1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@H]3NC(/C(/C#N)=C/C3CC3)=O)=O)[s]3)c3ncc1)C2=O PYJBXFHIRKFKPI-IXBQUWKISA-N 0.000 description 1
- VNCUMAWUTICNOY-JKSUJKDBSA-N CC(C)Cc(nc1)cc(C)c1N(c1ccnc2c1c(N1)c(C(N[C@H](CCC3)[C@H]3N)=O)[s]2)C1=O Chemical compound CC(C)Cc(nc1)cc(C)c1N(c1ccnc2c1c(N1)c(C(N[C@H](CCC3)[C@H]3N)=O)[s]2)C1=O VNCUMAWUTICNOY-JKSUJKDBSA-N 0.000 description 1
- NPFWBEIFYAXDPP-SJORKVTESA-N CC(C)Oc(cc1)cc(C)c1N(c1c(c(N2)c(C(N[C@@H](CC3)C[C@@H]3NC(C=C)=O)=O)[s]3)c3ncc1)C2=O Chemical compound CC(C)Oc(cc1)cc(C)c1N(c1c(c(N2)c(C(N[C@@H](CC3)C[C@@H]3NC(C=C)=O)=O)[s]3)c3ncc1)C2=O NPFWBEIFYAXDPP-SJORKVTESA-N 0.000 description 1
- QCPHYNCAKBFILR-SJORKVTESA-N CC(C)Oc(cc1)cc(C)c1N(c1ccnc2c1c(N1)c(C(N[C@@H](CC3)C[C@@H]3NC(CNC)=O)=O)[s]2)C1=O Chemical compound CC(C)Oc(cc1)cc(C)c1N(c1ccnc2c1c(N1)c(C(N[C@@H](CC3)C[C@@H]3NC(CNC)=O)=O)[s]2)C1=O QCPHYNCAKBFILR-SJORKVTESA-N 0.000 description 1
- BKKIOTQNBLYUGA-UHFFFAOYSA-N CC(C)Oc(cc1C)ncc1N(C(Nc1c(C(NCCNC(C=C)=O)=O)[s]2)OC)c3c1c2ncc3 Chemical compound CC(C)Oc(cc1C)ncc1N(C(Nc1c(C(NCCNC(C=C)=O)=O)[s]2)OC)c3c1c2ncc3 BKKIOTQNBLYUGA-UHFFFAOYSA-N 0.000 description 1
- OIVXNNROORTYCG-JIDIRTRFSA-N CC(N[C@@H](CCC1)/C1=N/C(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O)=O Chemical compound CC(N[C@@H](CCC1)/C1=N/C(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O)=O OIVXNNROORTYCG-JIDIRTRFSA-N 0.000 description 1
- IRBQOEDUKLAEJZ-WOJBJXKFSA-N CC(N[C@H](CCC1)C[C@@H]1NC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O)=O Chemical compound CC(N[C@H](CCC1)C[C@@H]1NC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O)=O IRBQOEDUKLAEJZ-WOJBJXKFSA-N 0.000 description 1
- JTOYEYNFXIKFEC-FGZHOGPDSA-N CC(N[C@H](CCCC1)[C@@H]1NC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O)=O Chemical compound CC(N[C@H](CCCC1)[C@@H]1NC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O)=O JTOYEYNFXIKFEC-FGZHOGPDSA-N 0.000 description 1
- SKBRPFMPODKPAQ-GWQXNCQPSA-N CC(N[C@H]1C(CNC(c([s]c2c3c(N4c(cc5)c(C)cc5Oc5ccccc5)ccn2)c3NC4=O)=O)CCCC1)=O Chemical compound CC(N[C@H]1C(CNC(c([s]c2c3c(N4c(cc5)c(C)cc5Oc5ccccc5)ccn2)c3NC4=O)=O)CCCC1)=O SKBRPFMPODKPAQ-GWQXNCQPSA-N 0.000 description 1
- VITPEFAXJDNIFP-LEWJYISDSA-N CCC(N[C@@H](CCC1)[C@@H]1NC(c([s]c1nccc(N2c(cc3)ccc3Oc3ccccc3)c11)c1NC2=O)=O)=O Chemical compound CCC(N[C@@H](CCC1)[C@@H]1NC(c([s]c1nccc(N2c(cc3)ccc3Oc3ccccc3)c11)c1NC2=O)=O)=O VITPEFAXJDNIFP-LEWJYISDSA-N 0.000 description 1
- MQUSJGYYIIAMIS-FCHUYYIVSA-N CCC(N[C@@H](CCCC1)[C@@H]1NC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O)=O Chemical compound CCC(N[C@@H](CCCC1)[C@@H]1NC(c([s]c1nccc(N2c(cc3)c(C)cc3Oc3ccccc3)c11)c1NC2=O)=O)=O MQUSJGYYIIAMIS-FCHUYYIVSA-N 0.000 description 1
- MQUSJGYYIIAMIS-FGZHOGPDSA-N CCC(N[C@H](CCCC1)[C@@H]1NC(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O)=O Chemical compound CCC(N[C@H](CCCC1)[C@@H]1NC(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O)=O MQUSJGYYIIAMIS-FGZHOGPDSA-N 0.000 description 1
- MQUSJGYYIIAMIS-YADHBBJMSA-N CCC(N[C@H](CCCC1)[C@H]1NC(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O)=O Chemical compound CCC(N[C@H](CCCC1)[C@H]1NC(c([s]c1c2c(N3c(cc4)c(C)cc4Oc4ccccc4)ccn1)c2NC3=O)=O)=O MQUSJGYYIIAMIS-YADHBBJMSA-N 0.000 description 1
- IFORKKQWHSIMOT-XXGTVTCJSA-N CN(C)C/C=C/C(N[C@H](CC1)C[C@H]1NC(c([s]c1nccc(N2c(cc3)cc(Cl)c3Oc3ccccc3)c11)c1NC2=O)=O)=O Chemical compound CN(C)C/C=C/C(N[C@H](CC1)C[C@H]1NC(c([s]c1nccc(N2c(cc3)cc(Cl)c3Oc3ccccc3)c11)c1NC2=O)=O)=O IFORKKQWHSIMOT-XXGTVTCJSA-N 0.000 description 1
- HCUQITXEGWKLRT-ZWKOTPCHSA-N Cc(cc(cc1)OC2CCOCC2)c1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@H]3N)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)OC2CCOCC2)c1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@H]3N)=O)[s]3)c3ncc1)C2=O HCUQITXEGWKLRT-ZWKOTPCHSA-N 0.000 description 1
- QXJMDEJZGKMMJG-VQTJNVASSA-N Cc(cc(cc1)Oc2c(C)nccc2)c1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@H]3NC(C=C)=O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2c(C)nccc2)c1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@H]3NC(C=C)=O)=O)[s]3)c3ncc1)C2=O QXJMDEJZGKMMJG-VQTJNVASSA-N 0.000 description 1
- RMKKDQADWSKFNP-UHFFFAOYSA-N Cc(cc(cc1)Oc2cc(COc(cccc3)c3C#N)ccc2)c1N(c1c(c(N2)c(C(OC)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2cc(COc(cccc3)c3C#N)ccc2)c1N(c1c(c(N2)c(C(OC)=O)[s]3)c3ncc1)C2=O RMKKDQADWSKFNP-UHFFFAOYSA-N 0.000 description 1
- BYDBRGFCKBMNDO-UHFFFAOYSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(Cl)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(Cl)=O)[s]3)c3ncc1)C2=O BYDBRGFCKBMNDO-UHFFFAOYSA-N 0.000 description 1
- YKBDBGSSFOHULY-SFHVURJKSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N(CC3)C[C@H]3N(C)C)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N(CC3)C[C@H]3N(C)C)=O)[s]3)c3ncc1)C2=O YKBDBGSSFOHULY-SFHVURJKSA-N 0.000 description 1
- GJBXSZCJQWXFSA-UHFFFAOYSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(NC)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(NC)=O)[s]3)c3ncc1)C2=O GJBXSZCJQWXFSA-UHFFFAOYSA-N 0.000 description 1
- OSUMLSRVTSSXLP-UXHICEINSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@@H](CC3)C[C@@H]3NC(CN(C)C)=O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@@H](CC3)C[C@@H]3NC(CN(C)C)=O)=O)[s]3)c3ncc1)C2=O OSUMLSRVTSSXLP-UXHICEINSA-N 0.000 description 1
- USMFSTVOXMVHFX-MOPGFXCFSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@@H](CC3)C[C@@H]3NC(CNC)=O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@@H](CC3)C[C@@H]3NC(CNC)=O)=O)[s]3)c3ncc1)C2=O USMFSTVOXMVHFX-MOPGFXCFSA-N 0.000 description 1
- NBTHIKMABCDQSO-PMACEKPBSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@@H](CCC3)[C@H]3NC(CN)=O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@@H](CCC3)[C@H]3NC(CN)=O)=O)[s]3)c3ncc1)C2=O NBTHIKMABCDQSO-PMACEKPBSA-N 0.000 description 1
- HVFCAODGYMLZHS-MXVIHJGJSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CC3)CC[C@@H]3NC(C=C)=O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CC3)CC[C@@H]3NC(C=C)=O)=O)[s]3)c3ncc1)C2=O HVFCAODGYMLZHS-MXVIHJGJSA-N 0.000 description 1
- MVGMAQAMXVZMBB-HDICACEKSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CC3)CC[C@H]3N)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CC3)CC[C@H]3N)=O)[s]3)c3ncc1)C2=O MVGMAQAMXVZMBB-HDICACEKSA-N 0.000 description 1
- OSUMLSRVTSSXLP-WOJBJXKFSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CC3)C[C@@H]3NC(CN(C)C)=O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CC3)C[C@@H]3NC(CN(C)C)=O)=O)[s]3)c3ncc1)C2=O OSUMLSRVTSSXLP-WOJBJXKFSA-N 0.000 description 1
- UYUFANMOPWIEHS-FCHUYYIVSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@H]3NC(CN(C)C)=O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@H]3NC(CN(C)C)=O)=O)[s]3)c3ncc1)C2=O UYUFANMOPWIEHS-FCHUYYIVSA-N 0.000 description 1
- XRSHYEIOILNXIN-RELWKKBWSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(NC(CC3)CCC3NC(/C(/C#N)=C/C3CC3)=O)=O)[s]2)C1=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(NC(CC3)CCC3NC(/C(/C#N)=C/C3CC3)=O)=O)[s]2)C1=O XRSHYEIOILNXIN-RELWKKBWSA-N 0.000 description 1
- SXQLTAPDAHGBDG-HDICACEKSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(N[C@H](CC3)CC[C@H]3O)=O)[s]2)C1=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(N[C@H](CC3)CC[C@H]3O)=O)[s]2)C1=O SXQLTAPDAHGBDG-HDICACEKSA-N 0.000 description 1
- UMJICMCUYGGUAU-QZTJIDSGSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(N[C@H](CC3)C[C@@H]3NC(CN)=O)=O)[s]2)C1=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(N[C@H](CC3)C[C@@H]3NC(CN)=O)=O)[s]2)C1=O UMJICMCUYGGUAU-QZTJIDSGSA-N 0.000 description 1
- RNQPBWKBJRDZHV-ZWKOTPCHSA-N Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(N[C@H](CCC3)C[C@H]3N)=O)[s]2)C1=O Chemical compound Cc(cc(cc1)Oc2ccccc2)c1N(c1ccnc2c1c(N1)c(C(N[C@H](CCC3)C[C@H]3N)=O)[s]2)C1=O RNQPBWKBJRDZHV-ZWKOTPCHSA-N 0.000 description 1
- OTRSFBJPGVKANY-ZWKOTPCHSA-N Cc(cc(cc1)Oc2cccnn2)c1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@H]3NC(C=C)=O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(cc1)Oc2cccnn2)c1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@H]3NC(C=C)=O)=O)[s]3)c3ncc1)C2=O OTRSFBJPGVKANY-ZWKOTPCHSA-N 0.000 description 1
- VBJUELWAGRIOKC-JKSUJKDBSA-N Cc(cc(nc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CC3)C[C@H]3N)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(cc(nc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CC3)C[C@H]3N)=O)[s]3)c3ncc1)C2=O VBJUELWAGRIOKC-JKSUJKDBSA-N 0.000 description 1
- MBBHAQKJGRFJRE-DLBZAZTESA-N Cc(nc(cc1)N(C=CC=C2)C2=O)c1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@H]3NC(C=C)=O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(nc(cc1)N(C=CC=C2)C2=O)c1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@H]3NC(C=C)=O)=O)[s]3)c3ncc1)C2=O MBBHAQKJGRFJRE-DLBZAZTESA-N 0.000 description 1
- OVNRFFHPHNOWQQ-IAGOWNOFSA-N Cc(nc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@@H]3N)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(nc(cc1)Oc2ccccc2)c1N(c1c(c(N2)c(C(N[C@H](CCC3)[C@@H]3N)=O)[s]3)c3ncc1)C2=O OVNRFFHPHNOWQQ-IAGOWNOFSA-N 0.000 description 1
- SHIIWDVLPYZXCW-UHFFFAOYSA-N Cc(nc1)ccc1Oc(cc1)ccc1N(c1c(c(N2)c(C(O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc(nc1)ccc1Oc(cc1)ccc1N(c1c(c(N2)c(C(O)=O)[s]3)c3ncc1)C2=O SHIIWDVLPYZXCW-UHFFFAOYSA-N 0.000 description 1
- CQBUNLFGXQMFSU-UHFFFAOYSA-N Cc1cc(Oc2ccccc2)ncc1N(c1c(c(N2)c(C(O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc1cc(Oc2ccccc2)ncc1N(c1c(c(N2)c(C(O)=O)[s]3)c3ncc1)C2=O CQBUNLFGXQMFSU-UHFFFAOYSA-N 0.000 description 1
- QIMUGVPFDNFUPE-RBUKOAKNSA-N Cc1cc(Oc2cnc(C)cc2)ncc1N(c1ccnc2c1c(N1)c(C(N[C@H](CCC3)[C@H]3NC(C=C)=O)=O)[s]2)C1=O Chemical compound Cc1cc(Oc2cnc(C)cc2)ncc1N(c1ccnc2c1c(N1)c(C(N[C@H](CCC3)[C@H]3NC(C=C)=O)=O)[s]2)C1=O QIMUGVPFDNFUPE-RBUKOAKNSA-N 0.000 description 1
- MKDQWWFDVFCDLL-DLBZAZTESA-N Cc1cc(Oc2nnccc2)ncc1N(c1c(c(N2)c(C(N[C@H](CCCC3)[C@H]3NC(C=C)=O)=O)[s]3)c3ncc1)C2=O Chemical compound Cc1cc(Oc2nnccc2)ncc1N(c1c(c(N2)c(C(N[C@H](CCCC3)[C@H]3NC(C=C)=O)=O)[s]3)c3ncc1)C2=O MKDQWWFDVFCDLL-DLBZAZTESA-N 0.000 description 1
- VOFQMEUQEBMKBJ-DLBZAZTESA-N N[C@@H](CCC1)[C@@H]1NC(c([s]c1nccc(N2c(cc3)cnc3Oc3ccccc3)c11)c1NC2=O)=O Chemical compound N[C@@H](CCC1)[C@@H]1NC(c([s]c1nccc(N2c(cc3)cnc3Oc3ccccc3)c11)c1NC2=O)=O VOFQMEUQEBMKBJ-DLBZAZTESA-N 0.000 description 1
- GAXQQEKGURKNTM-CABCVRRESA-N N[C@H](CC1)C[C@H]1NC(c([s]c1nccc(N2c(cc3)cnc3Oc3ccccc3)c11)c1NC2=O)=O Chemical compound N[C@H](CC1)C[C@H]1NC(c([s]c1nccc(N2c(cc3)cnc3Oc3ccccc3)c11)c1NC2=O)=O GAXQQEKGURKNTM-CABCVRRESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265836P | 2015-12-10 | 2015-12-10 | |
| US62/265,836 | 2015-12-10 | ||
| PCT/US2016/065954 WO2017100662A1 (en) | 2015-12-10 | 2016-12-09 | Polycyclic compounds as inhibitors of bruton's tyrosine kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180093974A KR20180093974A (ko) | 2018-08-22 |
| KR102103395B1 true KR102103395B1 (ko) | 2020-04-23 |
Family
ID=57681784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187018900A Active KR102103395B1 (ko) | 2015-12-10 | 2016-12-09 | 브루톤 티로신 키나제의 억제제로서의 폴리사이클릭 화합물 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US10717745B2 (https=) |
| EP (2) | EP3386991B1 (https=) |
| JP (2) | JP6835846B2 (https=) |
| KR (1) | KR102103395B1 (https=) |
| CN (2) | CN108884106A (https=) |
| AR (1) | AR107042A1 (https=) |
| AU (1) | AU2016366541B2 (https=) |
| BR (1) | BR112018011526B1 (https=) |
| CA (1) | CA3007990C (https=) |
| CY (1) | CY1123263T1 (https=) |
| DK (1) | DK3386991T3 (https=) |
| EA (1) | EA035168B1 (https=) |
| ES (1) | ES2805835T3 (https=) |
| HR (1) | HRP20201193T1 (https=) |
| HU (1) | HUE049502T2 (https=) |
| IL (1) | IL259863B (https=) |
| JO (1) | JO3794B1 (https=) |
| LT (1) | LT3386991T (https=) |
| MA (2) | MA53110A (https=) |
| MD (1) | MD3386991T2 (https=) |
| ME (1) | ME03803B (https=) |
| MX (1) | MX387590B (https=) |
| PL (1) | PL3386991T3 (https=) |
| PT (1) | PT3386991T (https=) |
| RS (1) | RS60604B1 (https=) |
| SI (1) | SI3386991T1 (https=) |
| SM (1) | SMT202000404T1 (https=) |
| TW (1) | TWI729047B (https=) |
| UY (1) | UY37015A (https=) |
| WO (1) | WO2017100662A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| JO3793B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| US20200079790A1 (en) * | 2017-03-15 | 2020-03-12 | Janssen Sciences Ireland Unlimited Company | Methods of selective aryl- and heteroaryl-nitrogen bond formation |
| CN108164397B (zh) * | 2018-01-18 | 2020-11-13 | 暨南大学 | 一类邻苯二酚衍生物及其制备方法 |
| US20190375749A1 (en) | 2018-06-11 | 2019-12-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| ES2949871T3 (es) | 2019-04-11 | 2023-10-03 | Janssen Pharmaceutica Nv | Anillos de piridina que contienen derivados como inhibidores de MALT1 |
| US20230094146A1 (en) * | 2020-01-07 | 2023-03-30 | Medshine Discovery Inc. | Deuterated thienopyridine compound |
| EP4301365A1 (en) | 2021-03-03 | 2024-01-10 | Janssen Pharmaceutica NV | Combination therapy using a malt1 inhibitor and a btk inhibitor |
| AU2022284369A1 (en) | 2021-06-04 | 2024-01-25 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| JP2024526241A (ja) | 2021-06-30 | 2024-07-17 | ヤンセン ファーマシューティカ エヌ．ベー． | ブルトン型チロシンキナーゼの阻害剤及びその使用方法 |
| KR20240046170A (ko) | 2021-08-09 | 2024-04-08 | 얀센 파마슈티카 엔브이 | B-세포 악성종양의 치료에 사용하기 위한 조성물 |
| AU2023221549A1 (en) * | 2022-02-18 | 2024-10-03 | Janssen Pharmaceutica Nv | Synthesis of bruton's tyrosine kinase inhibitors |
| WO2025262118A1 (en) | 2024-06-20 | 2025-12-26 | Janssen Pharmaceutica Nv | Combination therapy using a malt1 inhibitor and a btk inhibitor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010056875A1 (en) | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3112415A1 (de) | 1981-03-28 | 1982-10-07 | Dynamit Nobel Ag, 5210 Troisdorf | Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden |
| US5430150A (en) | 1992-12-16 | 1995-07-04 | American Cyanamid Company | Retroviral protease inhibitors |
| US5300478A (en) | 1993-01-28 | 1994-04-05 | Zeneca Limited | Substituted fused pyrazolo compounds |
| JP2008513463A (ja) | 2004-09-15 | 2008-05-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | チアゾロピリジンキナーゼ阻害剤 |
| US7579356B2 (en) | 2005-05-04 | 2009-08-25 | Janssen Pharmaceutica Nv | Thia-tetraazaacenaphthylene kinase inhibitors |
| AU2006278627B2 (en) | 2005-08-08 | 2011-08-18 | Janssen Pharmaceutica, N.V. | Thiazolopyrimidine kinase inhibitors |
| US7427625B2 (en) * | 2006-02-08 | 2008-09-23 | Janssen Pharmaceutica, N.V. | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| EP2471789B9 (en) * | 2009-08-26 | 2015-03-25 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
| WO2011133609A2 (en) | 2010-04-19 | 2011-10-27 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of btk inhibitors |
| US20140249105A1 (en) | 2011-07-25 | 2014-09-04 | Diverchim | Novel ceramide analogues, processes for preparing same and uses thereof |
| EA201591685A1 (ru) | 2013-03-15 | 2016-01-29 | Янссен Фармацевтика Нв | Способы и промежуточные соединения для получения лекарственного препарата |
| EP3080103B9 (en) * | 2013-12-11 | 2018-09-19 | Biogen MA Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| JO3793B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
| WO2018103058A1 (en) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| WO2018103060A1 (en) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
-
2016
- 2016-12-08 JO JOP/2016/0256A patent/JO3794B1/ar active
- 2016-12-09 US US15/374,905 patent/US10717745B2/en active Active
- 2016-12-09 JP JP2018530000A patent/JP6835846B2/ja active Active
- 2016-12-09 RS RS20200884A patent/RS60604B1/sr unknown
- 2016-12-09 MA MA053110A patent/MA53110A/fr unknown
- 2016-12-09 TW TW105140760A patent/TWI729047B/zh active
- 2016-12-09 PT PT168201069T patent/PT3386991T/pt unknown
- 2016-12-09 WO PCT/US2016/065954 patent/WO2017100662A1/en not_active Ceased
- 2016-12-09 LT LTEP16820106.9T patent/LT3386991T/lt unknown
- 2016-12-09 AU AU2016366541A patent/AU2016366541B2/en active Active
- 2016-12-09 MD MDE20180978T patent/MD3386991T2/ro unknown
- 2016-12-09 DK DK16820106.9T patent/DK3386991T3/da active
- 2016-12-09 SM SM20200404T patent/SMT202000404T1/it unknown
- 2016-12-09 CA CA3007990A patent/CA3007990C/en active Active
- 2016-12-09 BR BR112018011526-6A patent/BR112018011526B1/pt active IP Right Grant
- 2016-12-09 HU HUE16820106A patent/HUE049502T2/hu unknown
- 2016-12-09 CN CN201680072125.2A patent/CN108884106A/zh active Pending
- 2016-12-09 CN CN202110404024.3A patent/CN113121562B/zh active Active
- 2016-12-09 UY UY0001037015A patent/UY37015A/es active IP Right Grant
- 2016-12-09 MX MX2018007075A patent/MX387590B/es unknown
- 2016-12-09 SI SI201630825T patent/SI3386991T1/sl unknown
- 2016-12-09 PL PL16820106T patent/PL3386991T3/pl unknown
- 2016-12-09 ES ES16820106T patent/ES2805835T3/es active Active
- 2016-12-09 EA EA201891378A patent/EA035168B1/ru unknown
- 2016-12-09 HR HRP20201193TT patent/HRP20201193T1/hr unknown
- 2016-12-09 MA MA43409A patent/MA43409B1/fr unknown
- 2016-12-09 ME MEP-2020-155A patent/ME03803B/me unknown
- 2016-12-09 KR KR1020187018900A patent/KR102103395B1/ko active Active
- 2016-12-09 EP EP16820106.9A patent/EP3386991B1/en active Active
- 2016-12-09 EP EP20177012.0A patent/EP3719022A1/en active Pending
- 2016-12-12 AR ARP160103789A patent/AR107042A1/es active IP Right Grant
-
2018
- 2018-06-07 IL IL259863A patent/IL259863B/en active IP Right Grant
-
2019
- 2019-05-15 US US16/413,453 patent/US10934310B2/en active Active
-
2020
- 2020-05-13 US US15/931,437 patent/US11319329B2/en active Active
- 2020-08-18 CY CY20201100769T patent/CY1123263T1/el unknown
-
2021
- 2021-02-04 JP JP2021016602A patent/JP7072690B2/ja active Active
-
2022
- 2022-03-25 US US17/705,225 patent/US12065446B2/en active Active
-
2024
- 2024-07-03 US US18/763,484 patent/US20240383914A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010056875A1 (en) | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102103395B1 (ko) | 브루톤 티로신 키나제의 억제제로서의 폴리사이클릭 화합물 | |
| WO2018103060A1 (en) | Inhibitors of bruton's tyrosine kinase and methods of their use | |
| AU2016366546B2 (en) | Inhibitors of Bruton's tyrosine kinase and methods of their use | |
| WO2018103058A1 (en) | Inhibitors of bruton's tyrosine kinase and methods of their use | |
| HK40038735A (en) | Polycyclic compounds as inhibitors of bruton's tyrosine kinase | |
| HK40052204A (en) | Polycyclic compounds as inhibitors of bruton's tyrosine kinase | |
| HK40052204B (en) | Polycyclic compounds as inhibitors of bruton's tyrosine kinase | |
| NZ742484B2 (en) | Polycyclic compounds as inhibitors of bruton's tyrosine kinase | |
| HK1262330B (en) | Polycyclic compounds as inhibitors of bruton's tyrosine kinase | |
| HK1262330A1 (en) | Polycyclic compounds as inhibitors of bruton's tyrosine kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PA0302 | Request for accelerated examination |
St.27 status event code: A-1-2-D10-D17-exm-PA0302 St.27 status event code: A-1-2-D10-D16-exm-PA0302 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 7 |